CTLA4 and breast cancer: Combination anti-PD-1 plus anti-CTLA-4 plus T-DM-1 was superior to T-DM-1 or anti-PD-1/CTLA-4 in a preclinical model.69 Lapatinib is an oral targeted inhibitor of EGFR and HER2, approved in combination with capecitabine or trastuzumab for metastatic HER2-positive breast cancer.